{"entity":{"id":"larkspur-biosciences","kind":"company","name":"Larkspur Biosciences","aka":[],"tldr":"Larkspur Biosciences makes medicines that remove proteins tumours rely on to survive stress. Its first medicine, taken daily, is being tested in solid tumours with a focus on bowel cancer, alone and with chemotherapy.","summary":"Larkspur Biosciences Inc., at One Canal Park, Cambridge, Massachusetts, develops first-in-class protein degraders aimed at stress-response pathways that tumours depend on, according to its website. Its lead LRK-4189, taken daily, is in a phase 1b/2 dose-escalation, expansion and optimisation trial (NCT07498725) alone and with mFOLFOX6 or FOLFIRI in solid tumours with a focus on colorectal cancer, at sites in Edinburgh, Nice and Strasbourg. Its first registered cancer trial, NCT07498725, was posted on ClinicalTrials.gov in March 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://larkspur.bio/"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07498725"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026 through a fetch summary because the site refused a plain request (HTTP 403). The website does not name the target of LRK-4189, and the registry record does not either, so no target is recorded.","Founding year, investors and financing were not stated on the page read."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://larkspur.bio/","stage":"startup","investors":[],"funding":[]},"route":"/companies/larkspur-biosciences/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"trial":[{"id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","route":"/trials/nct07498725/"}]}}